Purespring Therapeutics presents preclinical data at the 61st ERA Congress Data establishes the potential of AAV gene therapy to deliver transgenes to the podocyte to replace defective genes or to...
Purespring appoints Fredrik Erlandsson as Chief Medical Officer and Peter Mulcahy as Chief People Officer Appointments of Fredrik and Peter complete build-out of senior team London” 6 September...
Senior leadership team strengthened as Purespring prepares kidney gene therapy programmes for clinical development London€” 2 August 2023€” Purespring Therapeutics, the pioneering gene therapy...
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.
London— 07 September 2022— Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces the appointment of Alice Brown as its Chief Scientific Officer, effective immediately.
Purespring Therapeutics Expands Senior Team with Key Appointments Appointments include Dr Pille Harrison as VP of Clinical Development, Dr Aoife Waters as Medical Director, Nick Cetateanu as Head of...